Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025)
Fortrea Holdings (FTRE) reported Cash from Financing Activities of -$75.7 million for Q4 2025, down 6781.82% on a YoY basis from $1.1 million in Q4 2024, and down 51.4% quarter-over-quarter from -$50.0 million in Q3 2025.
Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025) Analysis & Trends
Fortrea Holdings has reported Cash from Financing Activities for 4 years, with the latest figure at -$75.7 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 6781.82% year-over-year to -$75.7 million; the trailing twelve-month figure through Mar 2026 stood at -$164.7 million (up 61.76% YoY), and the FY2025 full-year result was -$76.3 million, up 84.67% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$75.7 million, down from -$50.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $88.4 million in Q1 2025, with the low at -$504.0 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged -$54.8 million across 4 years, with a median of -$10.8 million in 2023.
- The largest YoY upside for Cash from Financing Activities was 315.02% in 2025 against a maximum downside of 6781.82% in 2025.
- Fortrea Holdings' Cash from Financing Activities stood at -$5.9 million in 2022, then tumbled by 30.51% to -$7.7 million in 2023, then jumped by 85.71% to -$1.1 million in 2024, then tumbled by 6781.82% to -$75.7 million in 2025.
- The last three Cash from Financing Activities figures came in at -$75.7 million (Q4 2025), -$50.0 million (Q3 2025), and -$39.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -75.70 Mn |
| Dec 31, 2025 | -75.70 Mn |
| Sep 30, 2025 | -50.00 Mn |
| Sep 30, 2025 | -50.00 Mn |
| Jun 30, 2025 | -39.00 Mn |
| Jun 30, 2025 | -39.00 Mn |
| Mar 31, 2025 | 88.40 Mn |
| Mar 31, 2025 | 88.40 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Jun 30, 2024 | -504.00 Mn |
| Jun 30, 2024 | -504.00 Mn |
| Mar 31, 2024 | 21.30 Mn |
| Mar 31, 2024 | 21.30 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Sep 30, 2023 | -7.70 Mn |